Flow Cytometry in oncological diagnosis

Definition and Principle

• Definition: Flow cytometry (FCM) is a laser-based biophysical technology used to rapidly profile, count, and isolate single cells in a fluid stream based on physical properties and specific surface or intracellular antigens.
• Basic Principle: Single-cell suspensions are targeted with fluorochrome-conjugated monoclonal antibodies. As cells pass individually through a laser beam, light is scattered in two pathways:
  • Forward Scatter (FSC): Corresponds to cell size.
  • Side Scatter (SSC): Corresponds to internal complexity/granularity.
• Emitted fluorescence is collected by photomultiplier tubes, digitized, and plotted via gating strategies to isolate abnormal blast or tumor populations.

Core Applications in Pediatric Oncology

1. Diagnosis and Classification of Acute Leukemias

FCM provides rapid diagnostic lineage commitment, differentiating Acute Lymphoblastic Leukemia (ALL) from Acute Myeloid Leukemia (AML) within hours. It aligns with the WHO classification of hematopoietic tumors.

2. Detection of Minimal Residual Disease (MRD)

• Significance: MRD monitoring via flow cytometry at End-of-Induction (Day 29) is the single most powerful prognostic tool and treatment stratification driver in pediatric B-ALL.
• Methodology: Utilizes multiparametric flow cytometry (typically 8-to-10 color panels) to detect LAIP (Leukemia-Associated Immunophenotypes) or "different from normal" maturation patterns.
• Sensitivity Threshold: Routinely achieves a sensitivity of detecting 1 leukemic cell among 10,000 normal cells (less than 0.01% or ${10}^{-4}$).

3. Evaluation of Pediatric Non-Hodgkin Lymphoma (NHL)

• Samples: Useful for immunophenotyping pleural fluid, ascitic fluid, cerebrospinal fluid (CSF), or fine-needle lymph node aspirates.
• Subtype Profiling:
  • Burkitt Lymphoma: Displays mature B-cell phenotype with intense CD19, CD20, CD10, and clonal surface light chain expression (Kappa or Lambda restriction) alongside negative TdT.
  • Anaplastic Large Cell Lymphoma (ALCL): Shows strong positivity for CD30.

4. Detection of Bone Marrow Metastasis in Solid Tumors

FCM identifies small clusters of non-hematopoietic malignant cells infiltrating pediatric bone marrow aspirates:

• Neuroblastoma: Characterized by CD56+, GD2+, CD99-, and CD45- gating profiles.
• Ewing Sarcoma: Characterized by strong CD99+, CD56-, and CD45- patterns.
• Rhabdomyosarcoma: Displays CD56+, Desmin+, and CD45- configurations.

Technical Advantages vs. Limitations

Advantages

• Speed: Delivers turnaround times within 2 to 4 hours, which is vital for initiating emergency induction therapy in hyperleukocytosis or superior vena cava syndrome.
• Multiparametric Sorting: Simultaneously analyzes 8 to 12 distinct surface and intracellular proteins on a single cell.
• Viability Filtering: Gating strategies effectively exclude dead cellular debris, decreasing false-positive background staining.

Limitations

• Loss of Architecture: Requires single-cell tissue disaggregation, losing vital spatial histopathological architecture.
• Antigen Loss/Shifting: Targeted therapies (e.g., Blinatumomab or CAR-T cells targeting CD19) can cause lineage switches or selective antigen loss, leading to false-negative MRD tracking.
• Artifact Risk: Relies on fresh, viable cells; heavily necrotic tumor specimens yield poor data quality.